发现和优化第一个ATP竞争型III型c-MET抑制剂的发现和优化
Iacovos N Michaelides1, Gavin W Collie1, Ulf Börjesson2
1Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
Journal of medicinal chemistry
|June 21, 2023
概括
研究人员开发了针对野生型 (WT) 和突变c-MET激酶的新型双重抑制剂,用于癌症治疗. 这些强效化合物显示出有前途的药理动力学和大脑暴露,促进了对c-MET驱动癌症的治疗.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 临床报告表明,在癌症治疗中需要使用野生型 (WT) 和突变c-MET激酶的双重抑制剂.
- c-MET激酶是各种癌症的关键标,其抑制是治疗开发的重点.
研究的目的:
- 设计和优化一种针对WT和D1228V突变c-MET的ATP竞争型III抑制剂的新型化学系列.
- 评估这些新型抑制剂的选择性,功效,药理动力学概况和脑透率.
主要方法:
- 基于结构的药物设计和计算分析被用于优化.
- 用生物化学和细胞分析来确定抑制剂活性.
- 在小鼠身上进行了体内药理动力学研究,以评估药物暴露和大脑透.
主要成果:
- 开发了一种具有纳米分子活性的高选择性c-MET抑制剂的化学系列.
- 灵干2被优化,证明了WT和D1228V突变c-MET的强烈抑制.
- 在大鼠研究中,优化的抑制剂表现出良好的药物动力学概况和有前途的自由大脑暴露.
结论:
- 这一新型化学系列代表了双c-MET抑制剂开发的有前途的进步.
- 这些发现支持设计大脑透药物治疗c-MET驱动癌症的潜力.
- 开发的抑制剂为依赖c-MET信号传递的癌症提供了潜在的治疗策略.
更多相关视频
07:03Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
2.7K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.8K
相关概念视频
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
ATP Synthase: Mechanism
14.8K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.8K
